StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q2 2026
122
Period ended Jun 30, 2026
Change on a year earlier
+14.0%
107 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026122+14.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026148+24.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025164+49.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025136+36.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025107+18.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025119+67.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024110+57.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024100+92.3%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202490+91.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202471+65.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202370+70.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202352+33.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202347+42.4%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202343-17.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202241+141.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202239–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up reblozyl (luspatercept — bms hematology/oncology royalty revenue) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_reblozyl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.